MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.294
+0.044
+1.34%
Closed 16:00 10/14 EDT
OPEN
3.294
PREV CLOSE
3.251
HIGH
3.294
LOW
3.294
VOLUME
505
TURNOVER
--
52 WEEK HIGH
4.270
52 WEEK LOW
2.040
MARKET CAP
20.48M
P/E (TTM)
-2.6474
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KZIA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

KZIA News

  • Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
  • PR Newswire.09/13 12:00
  • St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
  • PR Newswire.09/12 14:10
  • Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
  • PR Newswire.07/22 02:08
  • Kazia calls for greater awareness of the deadliest brain cancer in the US
  • PR Newswire.07/17 13:00

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About KZIA

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
More

Webull offers Kazia Therapeutics Ltd (ADR) (KZIA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.